To embed, copy and paste the code into your website or blog:
Under President Joe Biden, pharmaceutical regulation may see increased FDA guidance, new strategies to speed up innovation and regulatory review, and a renewed focus on diseases with unmet needs, among other expectations.
With President Joe Biden sworn in as the 46th US president, attention has turned to what actions he will take in his first 100 days in office, and beyond. While much of the president’s focus will initially be on the COVID-19 pandemic, increasing vaccination numbers, and economic relief, the pharmaceutical and biotechnology industries, which have been at the forefront of the executive branch’s attention since the start of COVID-19, will likely continue to garner significant policy focus. Specifically, over the next four years, we expect to see more Food and Drug Administration (FDA) independence, transparency, and funding; the application of new strategies to facilitate pharmaceutical product developm
Existing drugs could help treat covid-19. How do we know when to use them?
Jeffrey Klausner, The Washington Post
Jan. 27, 2021
FacebookTwitterEmail
Intensive care specialist Brad Butcher consults with nurse Mary Cox through the glass at UPMC Mercy Hospital in downtown Pittsburgh this month on how to treat covid-19 patients.Washington Post photo by Michael S. Williamson.
More than 400,000 Americans are dead from covid-19 in the 11 months since the first confirmed U.S. fatality from the disease. Current models predict an additional 200,000 could be dead by late spring. Intensive care units nationwide are nearly 80 percent full. Vaccination is going far more slowly than necessary to keep up with the epidemic.
Free Version of Cures Act Ready BlueButtonPRO Solution for EHRs & Payers Announced by Darena Solutions
Share Article
The free offering will allow EHRs and Payers to avoid the million dollar penalty and adopt FHIR® standards to meet the Cures Act requirements in a phased manner.
By offering our solution for free, we are proud to contribute to CMS and ONC s goal to leverage the robust nature of the FHIR® standard in democratizing healthcare technology development. DR. PAWAN JINDAL, PRESIDENT & CEO, DARENA SOLUTIONS ST. LOUIS (PRWEB) January 27, 2021 Darena Solutions announced today that it would offer a free version of its BlueButtonPRO solution called CuresConnect™ to EHRs and Payers. As part of the 21st Century Cures Act, the Office of the National Coordinator for Health Information Technology (ONC) and Centers for Medicare & Medicaid Services (CMS) issued two rules to implement interoperability and patient
Posted January 25th, 2021 for Ripon Society
Upton, McClain & Meijer Discuss Challenges Facing America & the Prospect of Bipartisan Cooperation in the Coming Year WASHINGTON, DC With the 46th President inaugurated and the 117th Congress officially underway, The Ripon Society held a virtual discussion this past Thursday with three Members of the U.S. House from Michigan, who shared their thoughts on some of the key challenges facing America and the prospect of bipartisan cooperation in the coming year. The Members were U.S. Rep. Fred Upton (MI-6), U.S. Rep. Lisa McClain (MI-10), and U.S. Rep. Peter Meijer (MI-3). McClain and Meijer are the two newest members of the Michigan state delegation, having been elected this past November, while Upton is beginning his 18th term in office, and as the longest serving member of the House from the Wolverine State is the delegation’s dean.